687 results on '"Albert, Nathalie L."'
Search Results
2. Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0
3. EANM perspectives for CZT SPECT in brain applications
4. Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome
5. EANM position on positron emission tomography in suspected functional pituitary neuroendocrine tumours
6. A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups
7. Patterns of intersectional tumor volumes in T2-weighted MRI and [18F]FET PET in adult glioma: a prospective, observational study
8. Regional desynchronization of microglial activity is associated with cognitive decline in Alzheimer’s disease
9. Associations between sex, body mass index and the individual microglial response in Alzheimer’s disease
10. Correction to: EANM perspectives for CZT SPECT in brain applications
11. The value of [18F]FET PET and somatostatin receptor imaging for differentiating pseudoprogression in residual meningioma
12. New Radiopharmaceuticals for Brain Tumors Imaging
13. Advances in PET imaging for meningioma patients.
14. EANM position paper: theranostics in brain tumours—the present and the future
15. Postoperative [68Ga]Ga-DOTA-TATE PET/CT imaging is prognostic for progression-free survival in meningioma WHO grade 1
16. Lenticulostriatal Ischemia Shows Relevant SSTR Expression on PET/CT Imaging Using the Novel SSTR-Targeting Peptide 18F-SiTATE
17. Investigational PET tracers in neuro-oncology-What's on the horizon? A report of the PET/RANO group.
18. Translating the theranostic concept to neuro-oncology: disrupting barriers
19. Individual regional associations between Aβ-, tau- and neurodegeneration (ATN) with microglial activation in patients with primary and secondary tauopathies
20. Highlights of the 35th EANM Annual Congress 2022, onsite edition in Barcelona, Spain: “FROM BARCELONA WITH LOVE”
21. Next-generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR-targeting peptide [18F]SiTATE
22. Dummy run for planning of isotoxic dose-escalated radiation therapy for glioblastoma used in the PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06)
23. Translocator protein (18kDA) (TSPO) marks mesenchymal glioblastoma cell populations characterized by elevated numbers of tumor-associated macrophages
24. Depletion and activation of microglia impact metabolic connectivity of the mouse brain
25. [18F]F-DED PET imaging of reactive astrogliosis in neurodegenerative diseases: preclinical proof of concept and first-in-human data
26. TSPO acts as an immune resistance gene involved in the T cell mediated immune control of glioblastoma
27. A convolutional neural network with self-attention for fully automated metabolic tumor volume delineation of head and neck cancer in [18F]FDG PET/CT
28. Translocator protein (TSPO)-PET as diagnostic and monitoring tool in COVID-19 related MRI-negative brainstem encephalitis: a case report
29. Neurological Disorders and Women's Health: Contribution of Molecular Neuroimaging Techniques
30. Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2022-12)
31. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group
32. A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups
33. TSPO PET signal using [18F]GE180 is associated with survival in recurrent gliomas
34. Combination of pre-treatment dynamic [18F]FET PET radiomics and conventional clinical parameters for the survival stratification in patients with IDH-wildtype glioblastoma
35. Acetyl-dl-leucine in cerebellar ataxia ([18F]-FDG-PET study): how does a cerebellar disorder influence cortical sensorimotor networks?
36. FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective
37. Distinct molecular profiles of skull bone marrow in health and neurological disorders
38. 2-[18F]-FDG PET for imaging brain involvement in patients with long COVID: perspective of the EANM Neuroimaging Committee
39. Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0
40. Case 25: Primary Diagnosis of an Isocitrate Dehydrogenase (IDH) Wild-Type Glioma
41. Correction to: Highlights of the 35th EANM Annual Congress 2022, onsite edition in Barcelona, Spain: “FROM BARCELONA WITH LOVE”
42. Correction to: Next‑generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR‑targeting peptide [18F]SiTATE
43. Feasibility of [68Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma
44. Translocator protein (18kDa) TSPO: a new diagnostic or therapeutic target for stress-related disorders?
45. PET imaging in patients with brain metastasis—report of the RANO/PET group
46. Case 32: Suspected Recurrence of Brain Metastasis After Radiotherapy
47. Case 27: Meningioma with Difficult Delineation on MRI
48. Deep learning based time-to-event analysis with PET, CT and joint PET/CT for head and neck cancer prognosis
49. Highlights of the 34th EANM Annual Congress 2021, 2nd virtual edition: “FROM HAMBURG WITH LOVE”
50. 68Ga-EMP-100 PET/CT—a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma—first in-human biodistribution and imaging results
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.